scispace - formally typeset
Open AccessJournal ArticleDOI

Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via beta2 integrin Mac-1.

TLDR
It is concluded that sRAGE interacts with Mac-1, thereby acting as an important proinflammatory and chemotactic molecule and was proven to act as a Chemotactic stimulus for neutrophils.
Abstract
Objective Receptor for advanced glycation end products (RAGE) is a cell surface molecule that binds a variety of ligands, including high mobility group box chromosomal protein 1 (HMGB-1), a potent proinflammatory cytokine. RAGE–ligand interaction leads to an inflammatory response. A truncated form of the receptor, soluble RAGE (sRAGE), has been suggested to function as a decoy abrogating cellular activation, but its endogenous activity is not fully understood. We undertook this study to assess the properties of sRAGE in vivo and in vitro and to analyze the role of sRAGE in HMGB-1–induced arthritis. Methods Mice were injected intraarticularly with HMGB-1 and treated systemically with sRAGE prior to histologic joint evaluation. All animals were subjected to peritoneal lavage to assess the local effect of sRAGE treatment. For in vitro studies, mouse splenocytes were incubated with sRAGE followed by assessment of NF-κB activation and cytokine production. The chemotactic properties of sRAGE were investigated using in vitro migration assay. Results Soluble RAGE was determined to have proinflammatory properties since it gave rise to production of interleukin-6, tumor necrosis factor α, and macrophage inflammatory protein 2. This effect was triggered by interaction with leukocyte β2 integrin Mac-1 and was mediated via NF-κB. Systemic treatment with sRAGE significantly down-regulated HMGB-1–triggered arthritis, but the observed effect was due to a deviation of the inflammatory response from the joint to the peritoneal cavity rather than a genuine antiinflammatory effect. Apart from its proinflammatory properties, sRAGE was proven to act as a chemotactic stimulus for neutrophils. Conclusion We conclude that sRAGE interacts with Mac-1, thereby acting as an important proinflammatory and chemotactic molecule.

read more

Citations
More filters
Journal ArticleDOI

HMGB1 in Health and Disease

TL;DR: High-mobility group box 1 (HMGB1), the most abundant and well-studied HMG protein, senses and coordinates the cellular stress response and plays a critical role not only inside of the cell as a DNA chaperone, chromosome guardian, autophagy sustainer, and protector from apoptotic cell death, but also outside thecell as the prototypic damage associated molecular pattern molecule (DAMP).
Journal ArticleDOI

RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation

TL;DR: The Receptor for Advanced Glycation Endproducts [RAGE] is an evolutionarily recent member of the immunoglobulin super-family, encoded in the Class III region of the major histocompatability complex, and sits in a pivotal role, regulating metabolism, inflammation, and epithelial survival in the setting of stress.
Journal ArticleDOI

Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications.

TL;DR: Despite broad experimental evidence for the role of RAGES in chronic disease, knowledge of its physiological function is still missing, limiting predictions about safety of long-term inhibition of RAGE’s ligand interaction in chronic diseases.
Journal ArticleDOI

Damage-associated molecular patterns (DAMPs) in preterm labor with intact membranes and preterm PROM: a study of the alarmin HMGB1.

TL;DR: This study determined whether intra-amniotic infection/inflammation (IAI) is associated with changes in amniotic fluid concentrations of HMGB1; and localize immunoreactivity ofHMGB1 in the fetal membranes and umbilical cord of patients with chorioamnionitis.
Journal ArticleDOI

HMGB1 as biomarker and drug target

TL;DR: The development of isoform-specific HMGB1 inhibitors may potentiate and fine-tune the pharmacological control of inflammation, in particular the emerging and relatively unexplored small molecules-based approach.
References
More filters
Journal ArticleDOI

HMG-1 as a Late Mediator of Endotoxin Lethality in Mice

TL;DR: High mobility group-1 (HMG-1) protein was found to be released by cultured macrophages more than 8 hours after stimulation with endotoxin, TNF, or IL-1, and showed increased serum levels after endotoxin exposure, suggesting that this protein warrants investigation as a therapeutic target.
Journal ArticleDOI

RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides.

TL;DR: It is reported here that receptor for AGE (RAGE) is a central cell surface receptor for EN-RAGE (extracellular newly identified RAGE-binding protein) and related members of the S100/calgranulin superfamily.
Journal ArticleDOI

The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses

TL;DR: These features of RAGE allow the receptor to propagate cellular dysfunction in a number of pathophysiologically relevant situations, most often dictated by the formation and persistence of ligands in the tissues.
Journal ArticleDOI

The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin MEDIATION OF NEURITE OUTGROWTH AND CO-EXPRESSION OF RAGE AND AMPHOTERIN IN THE DEVELOPING NERVOUS SYSTEM

TL;DR: The receptor for advanced glycation end products (RAGE), a newly-identified member of the immunoglobulin superfamily, mediates interactions of AGE-modified proteins with endothelium and other cell types.
Journal ArticleDOI

Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts.

TL;DR: Findings indicate interaction between the advanced glycation endproducts and their receptor is involved in the development of accelerated atherosclerosis in diabetes, and identify this receptor as a new therapeutic target in diabetic macrovascular disease.
Related Papers (5)